Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis
To assess the effect of ribavirin on pulmonary function in infants with respiratory syncytial virus bronchiolitis, we performed a randomized (nonmatched), double blinded, placebo-controlled study of 19 infants with RSV bronchiolitis. Infants with underlying respiratory, cardiac or immunologic diseas...
Gespeichert in:
| Veröffentlicht in: | The Pediatric infectious disease journal 1993-03, Vol.12 (3), p.214-218 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 218 |
|---|---|
| container_issue | 3 |
| container_start_page | 214 |
| container_title | The Pediatric infectious disease journal |
| container_volume | 12 |
| creator | JANAI, HILLEL K STUTMAN, HARRIS R ZALESKA, MARGARET RUB, BENY EYZAGUIRRE, MARIO MARKS, MELVIN I NUSSBAUM, ELIEZER |
| description | To assess the effect of ribavirin on pulmonary function in infants with respiratory syncytial virus bronchiolitis, we performed a randomized (nonmatched), double blinded, placebo-controlled study of 19 infants with RSV bronchiolitis. Infants with underlying respiratory, cardiac or immunologic disease were excluded. Patients were given ribavirin (10) or placebo (9) via an aerosol generator for 18 hours/day for 3 days. Pulmonary function (dynamic compliance, total lung resistance) was calculated using a pneumotachographic method on Days 1, 2 and 7. Differneces between groups on clinical criteria were not found. Approximately one-half of each group showed increased compliance and decreased lung resistance after 24 to 48 hours of therapy. By Day 7 compliance had increased 30% in the placebo group and 210% in the ribavirin-treated infants (P = 0.05). Significant differences in the rate of change of lung resistance were not seen by Day 7. We conclude that previously noted improvements in the early course of respiratory syncytial virus bronchiolitis treated with ribavirin do not appear to be a result of measurable changes in pulmonary function. However, paradoxical increases in airway resistance were not found in patients treated with ribavirin. |
| doi_str_mv | 10.1097/00006454-199303000-00008 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00006454_199303000_00008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8451098</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3538-38b0caf50a85ad6d201c10b42ee58b6d8094231e6114eefc4364c9c08ea4a7d83</originalsourceid><addsrcrecordid>eNp1UU1PwyAYJkYz5_QnmHDwWoVCKT2axa_ExMTouaEULMpgAerSfy9zcze5vPB8JTwvABCja4ya-gblw2hFC9w0BJH8KrYQPwJzXJGyQA2vj8Ec8QYXhDF-Cs5i_MwKQjGagRmnVc7hc6BfTSe-TTAOKq2VTNA7uB7tyjsRJqhHJ5PJUOYnP7qPfNHCpQg3Jg0wqLg2QSSfpXFyckpGWJjjxgi74J0cjLcmmXgOTrSwUV3s5wK839-9LR-L55eHp-XtcyFJRXhBeIek0BUSvBI960uEJUYdLZWqeMd6jhpaEqwYxlQpLSlhVDYScSWoqHtOFoDvcmXwMQal23Uwq_yTFqN221z711x7aO4X2lovd9b12K1UfzDuq8r81Z4XUQqrg3DSxIOMsrJGNc0yupNtvE0qxC87blRoByVsGtr_9kZ-APtLiBM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>JANAI, HILLEL K ; STUTMAN, HARRIS R ; ZALESKA, MARGARET ; RUB, BENY ; EYZAGUIRRE, MARIO ; MARKS, MELVIN I ; NUSSBAUM, ELIEZER</creator><creatorcontrib>JANAI, HILLEL K ; STUTMAN, HARRIS R ; ZALESKA, MARGARET ; RUB, BENY ; EYZAGUIRRE, MARIO ; MARKS, MELVIN I ; NUSSBAUM, ELIEZER</creatorcontrib><description>To assess the effect of ribavirin on pulmonary function in infants with respiratory syncytial virus bronchiolitis, we performed a randomized (nonmatched), double blinded, placebo-controlled study of 19 infants with RSV bronchiolitis. Infants with underlying respiratory, cardiac or immunologic disease were excluded. Patients were given ribavirin (10) or placebo (9) via an aerosol generator for 18 hours/day for 3 days. Pulmonary function (dynamic compliance, total lung resistance) was calculated using a pneumotachographic method on Days 1, 2 and 7. Differneces between groups on clinical criteria were not found. Approximately one-half of each group showed increased compliance and decreased lung resistance after 24 to 48 hours of therapy. By Day 7 compliance had increased 30% in the placebo group and 210% in the ribavirin-treated infants (P = 0.05). Significant differences in the rate of change of lung resistance were not seen by Day 7. We conclude that previously noted improvements in the early course of respiratory syncytial virus bronchiolitis treated with ribavirin do not appear to be a result of measurable changes in pulmonary function. However, paradoxical increases in airway resistance were not found in patients treated with ribavirin.</description><identifier>ISSN: 0891-3668</identifier><identifier>EISSN: 1532-0987</identifier><identifier>DOI: 10.1097/00006454-199303000-00008</identifier><identifier>PMID: 8451098</identifier><identifier>CODEN: PIDJEV</identifier><language>eng</language><publisher>Baltimore, MD: Williams & Wilkins</publisher><subject>Aerosols ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Bronchiolitis - drug therapy ; Bronchiolitis - microbiology ; Bronchiolitis - physiopathology ; Double-Blind Method ; Female ; Humans ; Infant ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Respiratory Function Tests ; Respiratory Syncytial Viruses ; Respirovirus Infections - drug therapy ; Respirovirus Infections - physiopathology ; Ribavirin - administration & dosage ; Ribavirin - therapeutic use</subject><ispartof>The Pediatric infectious disease journal, 1993-03, Vol.12 (3), p.214-218</ispartof><rights>Williams & Wilkins 1993. All Rights Reserved.</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3538-38b0caf50a85ad6d201c10b42ee58b6d8094231e6114eefc4364c9c08ea4a7d83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4627074$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8451098$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JANAI, HILLEL K</creatorcontrib><creatorcontrib>STUTMAN, HARRIS R</creatorcontrib><creatorcontrib>ZALESKA, MARGARET</creatorcontrib><creatorcontrib>RUB, BENY</creatorcontrib><creatorcontrib>EYZAGUIRRE, MARIO</creatorcontrib><creatorcontrib>MARKS, MELVIN I</creatorcontrib><creatorcontrib>NUSSBAUM, ELIEZER</creatorcontrib><title>Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis</title><title>The Pediatric infectious disease journal</title><addtitle>Pediatr Infect Dis J</addtitle><description>To assess the effect of ribavirin on pulmonary function in infants with respiratory syncytial virus bronchiolitis, we performed a randomized (nonmatched), double blinded, placebo-controlled study of 19 infants with RSV bronchiolitis. Infants with underlying respiratory, cardiac or immunologic disease were excluded. Patients were given ribavirin (10) or placebo (9) via an aerosol generator for 18 hours/day for 3 days. Pulmonary function (dynamic compliance, total lung resistance) was calculated using a pneumotachographic method on Days 1, 2 and 7. Differneces between groups on clinical criteria were not found. Approximately one-half of each group showed increased compliance and decreased lung resistance after 24 to 48 hours of therapy. By Day 7 compliance had increased 30% in the placebo group and 210% in the ribavirin-treated infants (P = 0.05). Significant differences in the rate of change of lung resistance were not seen by Day 7. We conclude that previously noted improvements in the early course of respiratory syncytial virus bronchiolitis treated with ribavirin do not appear to be a result of measurable changes in pulmonary function. However, paradoxical increases in airway resistance were not found in patients treated with ribavirin.</description><subject>Aerosols</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Bronchiolitis - drug therapy</subject><subject>Bronchiolitis - microbiology</subject><subject>Bronchiolitis - physiopathology</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Respiratory Function Tests</subject><subject>Respiratory Syncytial Viruses</subject><subject>Respirovirus Infections - drug therapy</subject><subject>Respirovirus Infections - physiopathology</subject><subject>Ribavirin - administration & dosage</subject><subject>Ribavirin - therapeutic use</subject><issn>0891-3668</issn><issn>1532-0987</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UU1PwyAYJkYz5_QnmHDwWoVCKT2axa_ExMTouaEULMpgAerSfy9zcze5vPB8JTwvABCja4ya-gblw2hFC9w0BJH8KrYQPwJzXJGyQA2vj8Ec8QYXhDF-Cs5i_MwKQjGagRmnVc7hc6BfTSe-TTAOKq2VTNA7uB7tyjsRJqhHJ5PJUOYnP7qPfNHCpQg3Jg0wqLg2QSSfpXFyckpGWJjjxgi74J0cjLcmmXgOTrSwUV3s5wK839-9LR-L55eHp-XtcyFJRXhBeIek0BUSvBI960uEJUYdLZWqeMd6jhpaEqwYxlQpLSlhVDYScSWoqHtOFoDvcmXwMQal23Uwq_yTFqN221z711x7aO4X2lovd9b12K1UfzDuq8r81Z4XUQqrg3DSxIOMsrJGNc0yupNtvE0qxC87blRoByVsGtr_9kZ-APtLiBM</recordid><startdate>199303</startdate><enddate>199303</enddate><creator>JANAI, HILLEL K</creator><creator>STUTMAN, HARRIS R</creator><creator>ZALESKA, MARGARET</creator><creator>RUB, BENY</creator><creator>EYZAGUIRRE, MARIO</creator><creator>MARKS, MELVIN I</creator><creator>NUSSBAUM, ELIEZER</creator><general>Williams & Wilkins</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199303</creationdate><title>Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis</title><author>JANAI, HILLEL K ; STUTMAN, HARRIS R ; ZALESKA, MARGARET ; RUB, BENY ; EYZAGUIRRE, MARIO ; MARKS, MELVIN I ; NUSSBAUM, ELIEZER</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3538-38b0caf50a85ad6d201c10b42ee58b6d8094231e6114eefc4364c9c08ea4a7d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Aerosols</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Bronchiolitis - drug therapy</topic><topic>Bronchiolitis - microbiology</topic><topic>Bronchiolitis - physiopathology</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Respiratory Function Tests</topic><topic>Respiratory Syncytial Viruses</topic><topic>Respirovirus Infections - drug therapy</topic><topic>Respirovirus Infections - physiopathology</topic><topic>Ribavirin - administration & dosage</topic><topic>Ribavirin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JANAI, HILLEL K</creatorcontrib><creatorcontrib>STUTMAN, HARRIS R</creatorcontrib><creatorcontrib>ZALESKA, MARGARET</creatorcontrib><creatorcontrib>RUB, BENY</creatorcontrib><creatorcontrib>EYZAGUIRRE, MARIO</creatorcontrib><creatorcontrib>MARKS, MELVIN I</creatorcontrib><creatorcontrib>NUSSBAUM, ELIEZER</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Pediatric infectious disease journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JANAI, HILLEL K</au><au>STUTMAN, HARRIS R</au><au>ZALESKA, MARGARET</au><au>RUB, BENY</au><au>EYZAGUIRRE, MARIO</au><au>MARKS, MELVIN I</au><au>NUSSBAUM, ELIEZER</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis</atitle><jtitle>The Pediatric infectious disease journal</jtitle><addtitle>Pediatr Infect Dis J</addtitle><date>1993-03</date><risdate>1993</risdate><volume>12</volume><issue>3</issue><spage>214</spage><epage>218</epage><pages>214-218</pages><issn>0891-3668</issn><eissn>1532-0987</eissn><coden>PIDJEV</coden><abstract>To assess the effect of ribavirin on pulmonary function in infants with respiratory syncytial virus bronchiolitis, we performed a randomized (nonmatched), double blinded, placebo-controlled study of 19 infants with RSV bronchiolitis. Infants with underlying respiratory, cardiac or immunologic disease were excluded. Patients were given ribavirin (10) or placebo (9) via an aerosol generator for 18 hours/day for 3 days. Pulmonary function (dynamic compliance, total lung resistance) was calculated using a pneumotachographic method on Days 1, 2 and 7. Differneces between groups on clinical criteria were not found. Approximately one-half of each group showed increased compliance and decreased lung resistance after 24 to 48 hours of therapy. By Day 7 compliance had increased 30% in the placebo group and 210% in the ribavirin-treated infants (P = 0.05). Significant differences in the rate of change of lung resistance were not seen by Day 7. We conclude that previously noted improvements in the early course of respiratory syncytial virus bronchiolitis treated with ribavirin do not appear to be a result of measurable changes in pulmonary function. However, paradoxical increases in airway resistance were not found in patients treated with ribavirin.</abstract><cop>Baltimore, MD</cop><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>Williams & Wilkins</pub><pmid>8451098</pmid><doi>10.1097/00006454-199303000-00008</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0891-3668 |
| ispartof | The Pediatric infectious disease journal, 1993-03, Vol.12 (3), p.214-218 |
| issn | 0891-3668 1532-0987 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00006454_199303000_00008 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Aerosols Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Bronchiolitis - drug therapy Bronchiolitis - microbiology Bronchiolitis - physiopathology Double-Blind Method Female Humans Infant Male Medical sciences Pharmacology. Drug treatments Respiratory Function Tests Respiratory Syncytial Viruses Respirovirus Infections - drug therapy Respirovirus Infections - physiopathology Ribavirin - administration & dosage Ribavirin - therapeutic use |
| title | Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T09%3A53%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ribavirin%20effect%20on%20pulmonary%20function%20in%20young%20infants%20with%20respiratory%20syncytial%20virus%20bronchiolitis&rft.jtitle=The%20Pediatric%20infectious%20disease%20journal&rft.au=JANAI,%20HILLEL%20K&rft.date=1993-03&rft.volume=12&rft.issue=3&rft.spage=214&rft.epage=218&rft.pages=214-218&rft.issn=0891-3668&rft.eissn=1532-0987&rft.coden=PIDJEV&rft_id=info:doi/10.1097/00006454-199303000-00008&rft_dat=%3Cpubmed_cross%3E8451098%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8451098&rfr_iscdi=true |